Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria

Parasite Immunology

Volumn 37, Issue 11, 2015, Pages 599-604

  Howland, S W ^a   Ng, G X P ^a,b   Chia, S K ^a,c   Renia L ^a,b,c  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Brain; Cerebral malaria; Cross presentation; Malaria; Proteasome inhibitor

Indexed keywords

ARTESUNATE; BORTEZOMIB; CARFILZOMIB; ONX 0914; PARASITE ANTIGEN; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; OLIGOPEPTIDE; PR-957;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN MALARIA; CROSS PRESENTATION; DRUG TREATMENT FAILURE; ENDOTHELIUM CELL; FEMALE; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; ANIMAL; ANTIGEN PRESENTATION; BRAIN; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IN VITRO STUDY; MALARIA FALCIPARUM; MALARIA, CEREBRAL; METABOLISM; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM BERGHEI;

ANIMALS; ANTIGEN PRESENTATION; ANTIMALARIALS; BORTEZOMIB; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; IN VITRO TECHNIQUES; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PLASMODIUM BERGHEI; PROTEASOME INHIBITORS;

EID: 84945127376     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12277     Document Type: Article

References (19)

1. Milner DA Jr, Whitten RO, Kamiza S, et al. The systemic pathology of cerebral malaria in African children. Front Cell Infect Microbiol 2014; 4: 104.
2. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647-1657.
3. Langhorne J, Buffet P, Galinski M, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. 2011; 10: 23.
4. Howland SW, Claser C, Poh CM, Gun SY & Renia L. Pathogenic CD8+ T cells in experimental cerebral malaria. Semin Immunopathol 2015; 37: 221-231.
5. Howland SW, Poh CM & Renia L. Activated Brain Endothelial Cells Cross-Present Malaria Antigen. PLoS Pathog 2015; 11: e1004963.
6. Howland SW, Poh CM, Gun SY, et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO Mol Med 2013; 5: 916-931.
7. Miller Z, Ao L, Kim KB & Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des 2013; 19: 4140-4151.
8. Muchamuel T, Basler M, Aujay MA, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-787.
9. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82: 110-122.
10. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002; 99: 14374-14379.
11. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
12. Basler M, Dajee M, Moll C, Groettrup M & Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol. 2010; 185: 634-641.
13. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
14. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-3290.
15. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
16. Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011; 39: 1873-1882.
17. Kreidenweiss A, Kremsner PG & Mordmuller B. Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J 2008; 7: 187.
18. Reynolds JM, El Bissati K, Brandenburg J, Gunzl A & Mamoun CB. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B. BMC Clin Pharmacol 2007; 7: 13.
19. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734-2743.